PCDH1, a Poor Prognostic Biomarker and Potential Target for Pancreatic Adenocarcinoma Metastatic Therapy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Nov 14

PMID 37957639

Authors

Xingyi Du

Xiaoyu Yi

Xiaocui Zou

Yuan Chen

YanHong Tai

Xuhong Ren

Xinhua He

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic adenocarcinoma (PAAD) is an aggressive solid tumour characterised by few early symptoms, high mortality, and lack of effective treatment. Therefore, it is important to identify new potential therapeutic targets and prognostic biomarkers of PAAD.

Methods: The Cancer Genome Atlas and Genotype-Tissue Expression databases were used to identify the expression and prognostic model of protocadherin 1 (PCDH1). The prognostic performance of risk factors and diagnosis of patients with PAAD were evaluated by regression analysis, nomogram, and receiver operating characteristic curve. Paraffin sections were collected from patients for immunohistochemistry (IHC) analysis. The expression of PCDH1 in cells obtained from primary tumours or metastatic biopsies was identified using single-cell RNA sequencing (scRNA-seq). Real-time quantitative polymerase chain reaction (qPCR) and western blotting were used to verify PCDH1 expression levels and the inhibitory effects of the compounds.

Results: The RNA and protein levels of PCDH1 were significantly higher in PAAD cells than in normal pancreatic ductal cells, similar to those observed in tissue sections from patients with PAAD. Aberrant methylation of the CpG site cg19767205 and micro-RNA (miRNA) hsa-miR-124-1 may be important reasons for the high PCDH1 expression in PAAD. Up-regulated PCDH1 promotes pancreatic cancer cell metastasis. The RNA levels of PCDH1 were significantly down-regulated following flutamide treatment. Flutamide reduced the percentage of PCDH1 RNA level in PAAD cells Panc-0813 to < 50%. In addition, the PCDH1 protein was significantly down-regulated after Panc-0813 cells were incubated with 20 µM flutamide and proves to be a potential therapeutic intervention for PAAD.

Conclusion: PCDH1 is a key prognostic biomarker and promoter of PAAD metastasis. Additionally, flutamide may serve as a novel compound that down-regulates PCDH1 expression as a potential treatment for combating PAAD progression and metastasis.

Citing Articles

Analysis of single nuclear chromatin accessibility reveals unique myeloid populations in human pancreatic ductal adenocarcinoma.

Pratt H, Ma L, Dziadowicz S, Ott S, Whalley T, Szomolay B Clin Transl Med. 2024; 14(3):e1595.

PMID: 38426634 PMC: 10905544. DOI: 10.1002/ctm2.1595.

References

Jangra R, Herbert A, Li R, Jae L, Kleinfelter L, Slough M . Protocadherin-1 is essential for cell entry by New World hantaviruses. Nature. 2018; 563(7732):559-563. PMC: 6556216. DOI: 10.1038/s41586-018-0702-1. View

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M . KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2022; 51(D1):D587-D592. PMC: 9825424. DOI: 10.1093/nar/gkac963. View

Peek S, Mah K, Weiner J . Regulation of neural circuit formation by protocadherins. Cell Mol Life Sci. 2017; 74(22):4133-4157. PMC: 5643215. DOI: 10.1007/s00018-017-2572-3. View

Luo J . KRAS mutation in pancreatic cancer. Semin Oncol. 2021; 48(1):10-18. PMC: 8380752. DOI: 10.1053/j.seminoncol.2021.02.003. View

Mizrahi J, Surana R, Valle J, Shroff R . Pancreatic cancer. Lancet. 2020; 395(10242):2008-2020. DOI: 10.1016/S0140-6736(20)30974-0. View

Modak D, Sotomayor M . Identification of an adhesive interface for the non-clustered δ1 protocadherin-1 involved in respiratory diseases. Commun Biol. 2019; 2:354. PMC: 6769022. DOI: 10.1038/s42003-019-0586-0. View

Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P . The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2016; 1(6):417-425. PMC: 4707969. DOI: 10.1016/j.cels.2015.12.004. View

Yu H, Yang F, Dong P, Liao S, Liu W, Zhao G . NDP52 tunes cortical actin interaction with astral microtubules for accurate spindle orientation. Cell Res. 2019; 29(8):666-679. PMC: 6796859. DOI: 10.1038/s41422-019-0189-9. View

Miyazaki Y, Matsubara S, Ding Q, Tsukasa K, Yoshimitsu M, Kosai K . Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition. Mol Cancer. 2016; 15(1):49. PMC: 4924257. DOI: 10.1186/s12943-016-0534-2. View

10.

Sano K, Tanihara H, Heimark R, Obata S, Davidson M, John T . Protocadherins: a large family of cadherin-related molecules in central nervous system. EMBO J. 1993; 12(6):2249-56. PMC: 413453. DOI: 10.1002/j.1460-2075.1993.tb05878.x. View

11.

Vasaikar S, Straub P, Wang J, Zhang B . LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2017; 46(D1):D956-D963. PMC: 5753188. DOI: 10.1093/nar/gkx1090. View

12.

Meng L, Zhang Y, Wu P, Li D, Lu Y, Shen P . CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2. Mol Cancer. 2022; 21(1):121. PMC: 9158112. DOI: 10.1186/s12943-022-01599-5. View

13.

Paulson A, Tran Cao H, Tempero M, Lowy A . Therapeutic advances in pancreatic cancer. Gastroenterology. 2013; 144(6):1316-26. DOI: 10.1053/j.gastro.2013.01.078. View

14.

Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E . Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508. PMC: 6697103. DOI: 10.1038/s41586-019-1186-3. View

15.

Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J . MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2017; 10(3):277-288. DOI: 10.2217/epi-2017-0118. View

16.

Kang R, Xie Y, Zhang Q, Hou W, Jiang Q, Zhu S . Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res. 2017; 27(7):916-932. PMC: 5518983. DOI: 10.1038/cr.2017.51. View

17.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

18.

Schweizer M, Yu E . AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers (Basel). 2017; 9(1). PMC: 5295778. DOI: 10.3390/cancers9010007. View

19.

Hu H, Wang Y, Ding X, He Y, Lu Z, Wu P . Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regulating NLRP3. Mol Cancer. 2018; 17(1):18. PMC: 5793431. DOI: 10.1186/s12943-018-0761-9. View

20.

Xu M, Liu C, Pu L, Lai J, Li J, Ning Q . Systemic analysis of the expression levels and prognosis of breast cancer-related cadherins. Exp Biol Med (Maywood). 2021; 246(15):1706-1720. PMC: 8719037. DOI: 10.1177/15353702211010417. View